Cancer Chemotherapy Center

Innovating safe and effective anti-cancer drugs and treatments

Gilteritinib overcomes lorlatinib resistance in ALK-rearranged cancer　 More

To identify molecular targets and compounds for cancer therapy

We discover and develop the novel molecular-targeted drugs by using Cancer Cell Informatics.

Telomeres, cell immortality and cancer stemness as therapeutic targets

We promote genome science-driven research for targeted therapy and personalized medicine

We focus the research between clinical samples and imaging the molecular target

Takahashi, M., Okamoto, Y., Kato, Y., Shirahama, H., Tsukahara, S., Sugimoto, Y. and Tomida, A.

Activating mutations in EGFR and PI3K promote ATF4 induction for NSCLC cell survival during amino acid deprivation.
Heliyon, in press (2023)
Tanaka, M. and Nakamura, T.

Targeting epigenetic aberrations of sarcoma in CRISPR era.
Genes Chromosomes Cancer, in press (2023)
Yamashita, K., Baba, S., Togashi, Y., Dobashi, A., Ae, K., Matsumoto, S., Tanaka, M., Nakamura, T. and Takeuchi, K.

Clinicopathologic and genetic characterization of angiofibroma of soft tissue: a study of 12 cases including two cases with AHRR::NCOA3 gene fusion.
Histopathology, in press (2023)
Isoyama, S., Tamaki, N., Noguchi, Y., Okamura, M., Yoshimatsu, Y., Kondo, T., Suzuki, T., Yaguchi, S. and Dan, S.

Subtype-selective induction of apoptosis in translocation-related sarcoma cells induced by PUMA and BIM upon treatment with pan-PI3K inhibitors.
Cell Death Dis., 14, 169 (2023)
Saeki, S., Kumegawa, K., Takahashi, Y., Yang, L., Osako, T., Yasen, M., Otsuji, K., Miyata, K., Yamakawa, K., Suzuka, J., Sakimoto, Y., Ozaki, Y., Takano, T., Sano, T., Noda, T., Ohno, S., Yao, R., Ueno, T. and Maruyama, R.

Transcriptomic intratumor heterogeneity of breast cancer patient-derived organoids may reflect the unique biological features of the tumor of origin.
Breast Cancer Res., 25, 21 (2023)